Aims: This phase 2, double-blind, randomized, placebo-controlled trial (ClinicalTrials.gov NCT02702011) with 4 sites in Japan investigated the pharmacodynamics (PD), pharmacokinetics (PK) and safety profile of empagliflozin in Japanese participants with type 1 diabetes mellitus (T1DM) as adjunctive therapy to insulin.
should enable patients to attain glycaemic targets (glycated haemoglobin [HbA1c] ≤ 7.0%), 1, 2 to decrease the risk of hypoglycaemia, 3 to prevent weight gain 4 and to reduce glucose variability. 5 Several antihyperglycaemic agents (ie, pramlintide, metformin and liraglutide) with low risk of hypoglycaemia and weight gain in participants with type 2 diabetes mellitus (T2DM) improve glycaemic control and/or decrease insulin dose and body weight as adjuncts to insulin therapy in participants with T1DM. 4, [6] [7] [8] [9] [10] However, these medications have limitations in T1DM, such as increased risk of undesirable effects (ie, nausea, vomiting, anorexia and hypoglycemia), 6 absence of sustained effect on glycaemic control, 8, 9 and increased rates of symptomatic hypoglycaemia, hyperglycaemic episodes with ketosis and diabetic ketoacidosis (DKA) when compared with placebo. 10 Therefore, an adjunct to insulin treatment with a more favourable benefit/risk profile would be highly desirable in patients with T1DM.
Selective sodium-glucose co-transporter 2 (SGLT2) inhibitors have a unique insulin-independent mode of action; these agents decrease renal glucose reabsorption, which leads to urinary glucose excretion (UGE), and, consequently, decreased blood glucose levels. In participants with T2DM, SGLT2 inhibitors improve glycaemic control, along with a decrease in weight and blood pressure, without increasing the risk of hypoglycaemia. 4 Sotagliflozin, canagliflozin and dapagliflozin as adjunct to insulin therapy in T1DM resulted in a higher proportion of study participants achieving glycaemic target compared with placebo, and reduced glycaemic variability, rate of hypoglycaemia, body weight and insulin dose. [11] [12] [13] [14] Moreover, adjunct therapy with SGLT2 inhibitors may offer benefits for T1DM management in paediatric populations in the future after the benefits and risks in adults are clearly established. 15 Indeed, based on the mode of action of SGLT2 inhibitors, it is important to adequately characterize potential risks associated with these agents in terms of ketoacidosis in T1DM, particularly as suboptimal insulin usage may contribute to this acute T1DM complication. Given that the benefit/risk profiles of these agents are currently under investigation, no combination therapy with SGLT2 inhibitor is approved for use in T1DM.
Empagliflozin is a highly selective SGLT2 inhibitor that improves glycaemic control in T2DM; empagliflozin was also shown in the EMPA-REG OUTCOME trial to reduce the risk of cardiovascular death by 38% and to reduce incident or worsening nephropathy by 39% in participants with T2DM with established cardiovascular disease. [16] [17] [18] [19] In the phase 2 EASE-1 trial in participants with T1DM, empagliflozin as adjunct to insulin improved glycaemic control, decreased glucose variability, body weight and insulin dose, and increased time spent in the glucose target range, without increasing the rate of hypoglycaemia or DKA compared with placebo. 20, 21 However, given that EASE-1 was a small, short-duration study of Caucasian participants, larger studies, as well as studies in participants with different demographics (eg, Asian participants whose body mass index [BMI] , body composition and diet are different), are required to investigate the potential therapeutic benefits of empagliflozin in patients with T1DM.
In this 4-week, double-blind, randomized, placebo-controlled trial, we aimed to assess the pharmacodynamics (PD) (effect of empagliflozin on UGE compared with placebo) of once-daily empagliflozin 2.5, 10 and 25 mg as adjunct therapy to insulin treatment in Japanese participants with T1DM. Additionally, we aimed to evaluate pharmacokinetic (PK) parameters, HbA1c, fasting plasma glucose (FPG), body weight, glucose exposure and variability assessed by continuous glucose monitoring (CGM), ketogenesis markers, insulin doses, carbohydrate intake, blood pressure, and overall empagliflozin safety and tolerability in these participants. We hypothesized that empagliflozin would exhibit PD, PK, and short-term efficacy and safety profiles in Japanese participants with T1DM consistent with those of non-Japanese participants as previously reported.
20,21
2 | MATERIALS AND METHODS
| Study details
This was a phase 2, double-blind, randomized, placebo-controlled, 
| Study population
Eligible participants included male and female adults (≥20 to ≤65 years), with T1DM who were treated for ≥12 months with multiple daily injections of insulin prior to study initiation (≥1 basal and ≥3 bolus injections, with total daily insulin dose needs of ≥0.3 to ≤1.5 U/ kg), and with HbA1c of ≥7.5% to ≤10.0% (National Glycohaemoglobin Figure S1 ).
| Double-blind treatment period
Participants who met inclusion criteria after the run-in period were 
| Efficacy
Blood samples, measured at a central laboratory, were taken for 
| Safety
The type and frequency of adverse events (AEs), coded using the 
| Statistical analysis
A total of 48 participants (12 in each group) was generally considered sufficient for the evaluation of PD, PK, exploratory efficacy, safety and tolerability of multiple doses. This sample size would result in an overall power of >99% to test the primary endpoint (change from baseline in 24-hour UGE on Day 7) in the empagliflozin 10 and 25 mg groups compared with placebo, assuming a type I error of 5% (2-sided) and differences in mean UGE of 106.4 and 104.8 g/24 h between empagliflozin 10 mg and empagliflozin 25 mg, respectively, and placebo, with standard deviation of 27.3 g/24 h. 20 An analysis of covariance (ANCOVA) model was used to compare the primary endpoint between empagliflozin groups and placebo.
The primary analysis included all randomized participants who were treated with ≥1 dose of study drug and for whom there was
24-h UGE at baseline and on Day 1 or Day 7 (full analysis set [FAS])
with last observation carried forward imputation. PK analysis included participants who were treated with ≥1 dose of study drug (treated set) and with ≥1 PK observation and no relevant protocol violations.
Missing and undetectable concentration data were ignored and were not replaced. Descriptive statistics of concentrations at specific timepoints were calculated only when ≥2/3 of the individuals had concentrations within the validated range. PK parameters were calculated using Phoenix WinNonlin (version 6.3, Princeton, New Jersey), applying a non-compartmental method. An ANCOVA model with treatment as a fixed effect and baseline as a linear covariate was fitted to the efficacy endpoints on Days 1, 7 and 28, and was used to determine the treatment effect of different doses of empagliflozin compared with placebo. Safety was analysed in the treated set and is presented using descriptive statistics. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, North Carolina).
3 | RESULTS
| Participant disposition
Among 71 enrolled participants, 48 were randomized and treated with ≥1 dose of placebo (n = 11), empagliflozin 2.5 mg (n = 13), empagliflozin 10 mg (n = 12) or empagliflozin 25 mg (n = 12) ( Figure S2 ). The most frequent reason for discontinuation before randomization was failure to meet HbA1c inclusion criterion (15 participants). A total of 47 participants (97.9%) completed the 4-week trial.
| Demographic and baseline clinical characteristics
Baseline characteristics were similar across treatment groups, with the exception of a higher percentage of male participants, lower baseline mean HbA1c and longer time since T1DM diagnosis in the empagliflozin 25 mg group and a higher UGE in the empagliflozin 10 mg group (Table 1) .
| Pharmacodynamics
Concerning urinary glucose excretion, all empagliflozin doses significantly increased 24-hour UGE compared with placebo in a dosedependent manner ( Figure 1A) . 
| Pharmacokinetics
Empagliflozin was rapidly absorbed after single and multiple oral doses, reaching peak levels approximately 1.5 hours after dosing ( Figure S3 ). Thereafter, plasma concentrations showed a decline, with a rapid distribution phase and a slower elimination phase. Figure S5 ).
| Body weight
Empagliflozin treatment significantly decreased body weight compared with placebo on Day 28 in a dose-dependent manner (adjusted mean difference: 2.5 mg, −1.37 kg; 10 mg, −1.47 kg; 25 mg, −1.70 kg)
( Figure 1E ).
| Blood pressure
Small reductions from baseline in SBP and DBP were reported in the empagliflozin 10 mg group on Days 7 and 28 (Table S1 ). 
| Safety and tolerability
All three empagliflozin doses were generally well tolerated. All participants reported at least 1 AE and at least 1 AE of hypoglycaemia, with the exception of one participant in the empagliflozin 2.5 mg group (Table 2) . Most AEs were considered drug related, and most drug- 
| Ketogenesis markers
Changes from baseline in AUC 0-24 h of BHB, acetoacetic acid, total ketone bodies and FFA were numerically greater at Day 7 in all empagliflozin groups compared with placebo and were dose dependent ( Figure 3A and B and Figure S6A -S6C). Dose-dependent increases in mean BHB were observed also at Day 28 ( Figure 3B ).
| DKA
No events meeting the criteria for DKA were reported by investigators or adjudicated by the committee.
| Hypoglycaemia
All but one participant experienced hypoglycaemia. There were no reports of hypoglycaemia requiring assistance in any group during the 4-week treatment period ( Table 2) . Rates of symptomatic hypoglycaemia with plasma glucose ≥54 mg/dL and ≤70 mg/dL and with plasma glucose <54 mg/dL were generally similar among all groups. The rate of asymptomatic hypoglycaemia was numerically higher in the empagliflozin 25 mg group than in other groups.
| Renal function
No investigator reported decreased renal function in any participant during the randomized treatment period ( Table 2 ).
| Laboratory safety parameters
Overall, no significant changes from baseline in laboratory safety parameters were observed in the empagliflozin groups on Day 28 (Table S2 ).
| DISCUSSION
This is the first randomized placebo-controlled trial investigating the PK, PD, efficacy, safety, and tolerability of empagliflozin, as adjunct therapy to insulin in Japanese participants with T1DM. In this trial, empagliflozin increased UGE, improved glycaemic control and reduced body weight and total daily insulin dose without increasing the rate of hypoglycaemia. The PK of empagliflozin in Japanese participants with T1DM was similar to its PK in Japanese participants with T2DM. 22 In addition, this is the first report of empagliflozin treatment in Japanese participants with T1DM that showed dose-dependent increases in markers of ketogenesis, which were below clinically significant ranges.
Similar to the results of a previous trial in non-Japanese participants with T1DM, 20 empagliflozin significantly increased 24-hour UGE during 4 weeks of treatment in Japanese participants. In this study, the increase in UGE was accompanied by decreases in FPG and HbA1c, although the dose effect was less apparent than that for UGE, especially for HbA1c; this is probably explained by the short duration of treatment. By Day 28, the adjusted effect of empagliflozin 2.5 mg on UGE in Japanese participants with T1DM was similar to that of empagliflozin 10 mg in Japanese participants with T2DM (91.0 g/24 h vs 80.9 g/24 h). 22 Based on CGM assessment in this study, empagli- [2%] participants) after 24 weeks of treatment.
14 No DKA events were reported in the current study. Empagliflozin increased levels of serum ketone bodies in Japanese participants with T1DM in this study, as was previously observed in non-Japanese 23 and Japanese 24 participants with T2DM receiving empagliflozin. Mean serum BHB levels after 4 weeks of empagliflozin treatment were generally <0.5 mmol/L, with the highest individual BHB level at approximately 0.8 mmol/L, below the levels of total ketone bodies seen with physiological ketosis, such as prolonged fasting or exercise (1-2 mmol/L), 25 and well below levels seen in DKA (>3 mmol/L). 26 Importantly, special attention was paid to prevention of DKA during the study, including adoption of measures such as avoiding marked reduction in insulin dose. ≥1 AE leading to discontinuation 0 Our findings from this short-term trial indicate that empagliflozin is generally well tolerated in Japanese participants with T1DM, similar to participants from other countries. 20, 27 Consistent with empagliflozin's insulin-independent mechanism of action, the risk of hypoglycaemia was not increased. No decreased renal function and no events consistent with volume depletion were reported. We observed two cases of genital infection, consistent with genitourinary infection rates observed previously in Caucasian participants with T1DM 20 and consistent with the established association of these infections with SGLT2 inhibitor usage in participants with T2DM. 28 This study has several strengths. First, it is a double-blind, randomized, placebo-controlled trial evaluating the PD/PK effects of three dose levels of empagliflozin. Second, we used the same empagliflozin doses used in previous trials in non-Japanese participants, 20, 21, 27 allowing us to compare the PD, PK, efficacy and safety of empagliflozin among populations. Third, by using CGM, we were able to examine glucose exposure and variability, as well as time spent in the target glucose range in a blinded, unbiased fashion. This study does, however, have some limitations, including the small number of participants and its short duration, thus preventing conclusions concerning the long-term safety and efficacy of empagliflozin in Japanese participants with T1DM, which will need to be evaluated as part of phase 3 trials. Further, blood glucose readings by CGM are less accurate in the hypoglycaemic range, and measurements taken from interstitial fluid do not necessarily match the actual glucose concentrations in capillary blood. 29 In conclusion, in this short-term efficacy and safety study, administration of empagliflozin for 4 weeks in Japanese participants with T1DM, as adjunct to insulin therapy, increased UGE, improved glycaemic control and reduced total daily insulin needs and body weight. All three doses of empagliflozin were well tolerated, without increased risk of hypoglycaemia or DKA events. In Japanese participants with T1DM, the PK of empagliflozin was similar to that previously reported for participants with T2DM. The safety and efficacy of empagliflozin as adjunct to insulin therapy in T1DM will be further clarified when data from two large, international, phase 3 trials in non-Japanese participants with T1DM (EASE-2, NCT02414958 and EASE-3, NCT02580591) are available.
